The stock of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) reached all time low today, Oct, 31 and still has $3.03 target or 11.00% below today’s $3.41 share price. This indicates more downside for the $37.55 million company. This technical setup was reported by Barchart.com. If the $3.03 PT is reached, the company will be worth $4.13M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 27,931 shares traded hands. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has declined 22.80% since March 29, 2016 and is downtrending. It has underperformed by 26.27% the S&P500.
Analysts await Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) to report earnings on November, 14. They expect $-0.38 EPS, down 65.22% or $0.15 from last year’s $-0.23 per share. After $-0.39 actual EPS reported by Galmed Pharmaceuticals Ltd for the previous quarter, Wall Street now forecasts -2.56% EPS growth.
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) Ratings Coverage
Out of 2 analysts covering Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Galmed Pharmaceuticals Ltd has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, August 13 by Roth Capital. The stock of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) has “Buy” rating given on Monday, March 28 by H.C. Wainwright.
According to Zacks Investment Research, “Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.”
More notable recent Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) news were published by: Prnewswire.com which released: “Galmed Pharmaceuticals Third Quarter 2016 Conference Call and Webcast …” on October 31, 2016, also Prnewswire.com with their article: “Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the …” published on July 28, 2016, Prnewswire.com published: “Galmed Pharmaceuticals Announces the Appointment of Dr. Liat Hayardeny, Ph.D …” on September 08, 2016. More interesting news about Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) were released by: Prnewswire.com and their article: “Galmed Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” published on August 03, 2016 as well as Prnewswire.com‘s news article titled: “Galmed Pharmaceuticals Announces the Appointment of Professor Ran Oren, M.D …” with publication date: August 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.